The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of =20.
 
Jong Chul Park
Honoraria - Coherus Biosciences; MitoImmune; Selecxine
Consulting or Advisory Role - Hanall Biopharma; Hanmi Pharma
Research Funding - A2 Bio (Inst); A2 Biotherapeutics (Inst); Alentis Therapeutics (Inst); ALX Oncology (Inst); Ankyra Therapeutics (Inst); CUE Biopharma (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst)
 
Lisa Licitra
Honoraria - ALTIS Omnia Pharma Service Srl; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; Bicara Therapeutics; Boehringer Ingelheim; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Medscape LLC; Merck Healtcare KGaA; Merck Serono; MSD; MSD; Purple Biotech; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Aditya Shreenivas
Consulting or Advisory Role - Taiho Pharmaceutical (Inst)
Research Funding - Caris Life Sciences (Inst); Natera (Inst)
 
Yungpo Su
No Relationships to Disclose
 
Santosh Nair
Employment - Mid Florida Cancer Specialists
Research Funding - AstraZeneca; Exact Sciences; Merck; Pfizer; Regeneron
 
Andrea Teague
No Relationships to Disclose
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Siddharth Sheth
Honoraria - Coherus Biosciences; Eisai; InhibRx
Speakers' Bureau - Exelixis
Research Funding - AstraZeneca (Inst); Exelixis (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Merus
 
Hye Ryun Kim
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - ABL Bio; AstraZeneca; MSD Oncology; Ono Pharmaceutical; Roche/Genentech; Yuhan
Research Funding - AstraZeneca (Inst); Yuhan (Inst)
 
Jorge Martinalbo
Employment - Inhibrx Biosciences, Inc.
Stock and Other Ownership Interests - Inhibrx Biosciences, Inc.
 
Yaiza Diaz De Durana
Employment - Inhibrx Biosciences, Inc.
Stock and Other Ownership Interests - Inhibrx Biosciences, Inc.
 
Lane Senne
Employment - Inhibrx Biosciences, Inc.
Stock and Other Ownership Interests - Inhibrx Biosciences, Inc.
 
James Kalabus
Employment - Inhibrx Biosciences, Inc.
Stock and Other Ownership Interests - Inhibrx Biosciences, Inc.
Patents, Royalties, Other Intellectual Property - InhibRx
 
Josep Garcia
Employment - Inhibrx Biosciences, Inc.
Stock and Other Ownership Interests - Inhibrx Biosciences, Inc.
 
Dan Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; Coherus Biosciences; Coherus Biosciences; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); AVEO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)